public disclosure or (2) with all parties involved with intent to publicly disclose information related to the biomarker, target, or specific imaging study in a timely manner. The latter scenario may be covered under RCH as a project with the Biomarker Consortium. In all cases, the rules of engagement for the scope and timing of information shared throughout the process will be established before each project begins by the RCH facilitator and the pharmaceutical companies/academic partner involved, according to Dr. Dean F. Wong, professor of radiology and psychiatry, vice chair radiology research and section director of high resolution brain imaging at the Johns Hopkins University.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement